- Home
- ST vs AKRO Comparison
ST vs AKRO Comparison
Compare ST & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ST
- AKRO
- Stock Information
- Founded
- ST 1916
- AKRO 2017
- Country
- ST United States
- AKRO United States
- Employees
- ST N/A
- AKRO N/A
- Industry
- ST Industrial Machinery/Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ST Industrials
- AKRO Health Care
- Exchange
- ST Nasdaq
- AKRO Nasdaq
- Market Cap
- ST 4.1B
- AKRO 3.9B
- IPO Year
- ST 2010
- AKRO 2019
- Fundamental
- Price
- ST $28.27
- AKRO $54.20
- Analyst Decision
- ST Buy
- AKRO Strong Buy
- Analyst Count
- ST 13
- AKRO 6
- Target Price
- ST $34.08
- AKRO $82.50
- AVG Volume (30 Days)
- ST 1.4M
- AKRO 1.8M
- Earning Date
- ST 07-28-2025
- AKRO 08-08-2025
- Dividend Yield
- ST 1.70%
- AKRO N/A
- EPS Growth
- ST N/A
- AKRO N/A
- EPS
- ST 0.82
- AKRO N/A
- Revenue
- ST $3,837,310,000.00
- AKRO N/A
- Revenue This Year
- ST N/A
- AKRO N/A
- Revenue Next Year
- ST $4.03
- AKRO N/A
- P/E Ratio
- ST $34.68
- AKRO N/A
- Revenue Growth
- ST N/A
- AKRO N/A
- 52 Week Low
- ST $17.32
- AKRO $21.02
- 52 Week High
- ST $42.33
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ST 60.05
- AKRO 62.96
- Support Level
- ST $27.66
- AKRO $53.61
- Resistance Level
- ST $28.62
- AKRO $56.49
- Average True Range (ATR)
- ST 0.77
- AKRO 2.40
- MACD
- ST -0.03
- AKRO -0.08
- Stochastic Oscillator
- ST 83.50
- AKRO 65.93
About ST Sensata Technologies Holding plc
Sensata Technologies is a global supplier of sensors for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.